Navigating Treatment Options

The goal of CIDP treatment is to stop the immune system’s attack on your nerves, restore your physical function, and prevent long-term damage ^[1]. Because every patient responds differently, doctors use a “stepped” approach, starting with the most proven therapies and moving to specialized options if needed ^[2].

First-Line Treatments

The 2021 EAN/PNS guidelines recommend two primary options for starting treatment. Both are highly effective, but they work in very different ways ^[2].

• Intravenous Immunoglobulin (IVIg): This treatment uses healthy antibodies from donor plasma to “distract” or neutralize your overactive immune system ^[3]. It is usually given as a high “loading dose” over several days, followed by maintenance infusions. An example schedule might be every 3 to 4 weeks, but this varies based on your response ^[2].
  • Risks: While generally safe, IVIg can cause immediate reactions like headaches, fever, or nausea. More serious but rare risks include thromboembolic events (blood clots), acute kidney injury, aseptic meningitis, and hemolysis ^[4][5]. You should urgently report severe headache, chest pain, or breathing difficulty to your infusion team.
• Corticosteroids: Drugs like prednisone work by broadly suppressing your immune system. They can be taken as a daily pill or as a high-dose “pulse” (once a week) ^[2].
  • Risks: Long-term steroid use carries significant metabolic risks, including weight gain, high blood sugar (diabetes), bone thinning (osteoporosis, requiring bone protection), adrenal suppression, eye complications (like glaucoma or cataracts), mood effects, and increased risk of infection ^[6][2]. Do not stop steroids abruptly.

Maintenance and Home Care

Once your disease is stable, you may have the option to switch to Subcutaneous Immunoglobulin (SCIg). Instead of a long IV infusion, you use a small needle to self-administer the medication under your skin at home. An example schedule is once or twice a week, but the frequency and dose vary ^[7].

• Benefits: SCIg often results in fewer “ups and downs” in strength and fewer systemic side effects like the “IVIg headache” ^[8]. It also reduces infusion center visits.
• Challenges: Local site reactions (redness or swelling where you injected) are common, though they usually improve over time ^[8]. It requires home training, managing supplies, handling insurance, and sometimes caregiver assistance. It is not a 1:1 switch; some patients require dose adjustments to maintain their strength and avoid a “wear-off” effect after moving from IV to subcutaneous ^[7].

Second-Line and New Options

If IVIg and steroids do not work, your doctor may recommend Plasma Exchange (PLEX). This process involves pumping your blood through a machine that removes the liquid portion (plasma) containing the “bad” antibodies and replaces it with healthy fluid ^[2]. While very effective for rapid improvement, it requires specialized venous access and careful monitoring. Risks include line-related infections, bleeding, blood pressure changes, thrombosis, electrolyte abnormalities, and allergic reactions to the replacement fluids ^[9].

In 2024, a targeted therapy called Efgartigimod (Vyvgart Hytrulo) was FDA-approved for adults with CIDP ^[10]. It works as an FcRn blocker, which specifically lowers the overall levels of IgG antibodies in your blood ^[11].

• The ADHERE Trial: In the open-label phase, 66% of selected patients who had clinically meaningful deterioration achieved confirmed improvement. In the subsequent randomized phase, efgartigimod reduced the risk of confirmed deterioration versus placebo ^[12].
• Important Note: Because FcRn blockade lowers overall IgG, it carries infection risks and requires discussion about vaccination timing and immunoglobulin monitoring ^[12]. This is not a “magic switch” from IVIg, and your doctor will need to monitor you closely during the transition.

Targeted Therapy for Subtypes

If you have an Autoimmune Nodopathy (such as the anti-NF155 or anti-CNTN1 variants), standard IVIg often fails ^[13]. In these specific cases, a medication called Rituximab may be considered by a specialist, though this is often an off-label use based on observational evidence ^[14]. It targets and depletes the specific CD20-positive B-cells. Because rituximab significantly suppresses the immune system, it requires strict screening for latent infections like hepatitis B before you start and carries a prolonged infection risk ^[15][16].

Your care team will use objective tools, such as the INCAT disability scale or grip strength measurements, to track your progress and ensure your treatment is working effectively ^[17].